TNXP Tonix Pharmaceuticals Holding Corp

$TNXP calm down. Once Seth is fired and the CFO is replaced, the ATM abuse will stop, sales will improve, or they won’t! Woo hoo! BTMFD lol why not 🤷‍♀️ ♋️ Nonbinary is Beautiful 💚 🇺🇸 🌎 💊 🤕

$TNXP Thank you yet again for posting some very impressive Tonmya script numbers$$$. We and all of Tonix Pharmaceuticals are lucky to have you week in and week out.

$TNXP My personal and only personal, not enlightened, is that retail is being flushed out. I've been buying.

$TNXP Something just doesn't add up with TNXP. The narrative is: TONMYA is failing. Tonix is failing. SP is going lower. More dilution. RS coming. TONMYA is supposedly being lost. Yet Reddy just spent the time and money to develop a generic and attack FOUR TONMYA patents. At the same time, TONMYA went from ~$3.7M revenue in Q1 to ~$11M in Q2. So TONMYA supposedly sucks... but a major generic pharma company thinks it's worth fighting over? And are we really supposed to believe institutions bought shares just to short this thing into oblivion? Maybe I'm missing something, but the pieces don't fit. Reddy filing Paragraph IV isn't Reddy winning. It's a patent challenge. Tonix can sue, triggering the 30-month stay, and we've already seen Reddy settle/license products rather than always fight to the end. Could this eventually be a licence, settlement or regional deal? Who knows. But at these levels, the market seems to be pricing TONMYA like it's worthless. If it is, why is everyone fighting over it?

$TNXP a few ideas: 1) fire Seth as CEO and chairman of the board 2) promote COO Jessica Morris or hire someone who knows what they’re doing 3) fire CFO and, again, hire a real one 4) stop abusing ATM to pay Seth’s exorbitant salary 5) try to fix the price; Seth overpriced Tonmya BADLY. He is a maroon 💊

$TNXP We are 5,316k of annualised $ run rate away from my predicted level. I forecasted a 101,256k annualised run rate (74% recognition) and we are 5.3m away from that. Let's see if we can reach 110m annualised run rate by the end of September and we will hit the forecast!! FYI - I am predicting that we are currently at a Q3 revenue of $17.65M of revenue with 2 weeks left!!!! Good news so far!

$TNXP tell Seth To break the pattern: • Freeze non-core R&D burn immediately. • Declare a formal temporary ATM moratorium. • Prioritize 100% of runway on Tonmya US launch prep.

$TNXP this will rerate and explode some day, Q3 sales beat incoming, japan deal, Q4 entry at >$2M weekly Tonmya sales…any number of catalysts

$TNXP reading a lot of nonsense here. Patent challenge triggered massive sell-off. Now the volume dried out. Next it will rebound as it always does - just check the chart. Six major jumps within a year. Even without major catalyst - I expect it to he back to 8.2-8.9 before ER. And then, who knows.

$TNXP Are you crying or are you buying? Nothing has fundamentally changed here. A cheap Indian knock off company wants to rip off Tonmya because they know it's potential, the incoming lawsuit will stop them. Q3 ER results in one month and it will be another massive revenue beat. I'm still buying weekly, these prices allow me to get more shares each week.

$TNXP could you share the latest data on Tonmya? I'd like to know if what happened yesterday was just a bearish sell-off or if sales figures have actually plummeted. Thank you very much—you'd be helping a lot of your followers.

$TNXP Retail Trading Activity As we all expected, retail has been a fraction of all trades and it's clear there's been a huge push on flushing them out October 9th (8th Closing) Retail Activity: - $142.2K buys - $137.1K sells - $289.3K total TV October 8th - $5.2K NET October 7th - $13.9K NET October 6th - $63.9K NET October 5th - $53.5K NET I will be getting access to the institutional database at the end fot he month so keep your eyes peeled!

$TNXP any thoughts out there in Tonics Land? Investors should spend the weekend actually reading the filing and realize: Reddy has not won anything. Tonix has 45 days to sue. A timely suit will trigger the 30-month regulatory stay. The patents remain in force in the meantime. Meanwhile, Tonmya is actually generating revenue and prescriptions. Tonix reported $10.95 million of Tonmya revenue in Q2 2026, up dramatically from zero the prior year, while the company continues expanding commercialization

$TNXP Right now, I’m focused on TONMYA gaining market share, growing sales, securing new deals, and landing a strong partner. Let Dr. Reddy’s fight over whatever crumbs are left. 😉

$TNXP 💎💎 The most important thing right now is to see how Tonmya's sales have performed for the week ending September 18. Let's see if continues to be generous this week and shares the sales data. It's been half a month with the 50 new sales reps, and there were no holidays this week.

$TNXP Let's take the actual observed June→September growth rate and simply extend it. The 840 → 1,057 increase occurred over roughly 13 weeks. That's approximately 1.8% compounded weekly growth. If that continued: October Around 1,100–1,200 TRx/week November Around 1,200–1,300 December Around 1,300–1,450 January 2027 Around 1,400–1,550 March 2027 Potentially around 1,550–1,800 That's a math extension of current trend. If the new reps eventually generate only 25% of the productivity of the established reps, we could get roughly another: 130 weekly TRx At 50% productivity: ~265 additional TRx At 75%: ~400 additional TRx At mature productivity: ~530 additional TRx

$TNXP This kind of drop happened before. Everyone complained about how low it was, and soon after it went back up to $40+. Now we are here again, and instead of using this opportunity to load up, people are complaining again…

$TNXP Our payer situation has continued improving substantially. As of September 22, Tonix said commercial/government coverage had reached approximately 166 million covered lives, or 53% of U.S. lives, including 32 million Medicare lives.. That's very different from the Tonix of a couple years ago. A potential partner can look at: FDA-approved product → real prescriptions → real revenue → expanding payer coverage → Medicare access → sales force expansion → patent estate → potential additional indications That's an actual commercial asset. We are on the radar and very viable for any potential partner. A strategic partner doesn't necessarily need Tonix to have zero risk. They need the risk/reward economics to make sense.

$TNXP this is so undervalued.. What are your guys prediction for Q3 Sales ? I wouldn’t be surprised if we hit $25MIL

$TNXP Fantastic news; it demonstrates a major generics manufacturer's confidence that Tonmya sales will be very strong in two to three years and absolutely massive by 2032–2033.